<!DOCTYPE html>
<!--[if lt IE 9]><html class="lte-ie8" lang="en"><![endif]--><!--[if gt IE 8]><!--><html lang="en">
<!--<![endif]-->
  <head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta property="og:description" content="">
<meta property="og:title" content="Proposal to allow recipients of convalescent plasma for treatment of infection with SARS-CoV-2 to donate plasma for treatment of SARS-CoV-2 infected individuals">
<meta property="og:url" content="https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i">
<meta property="og:type" content="article">
<meta property="og:site_name" content="GOV.UK">
<meta name="twitter:card" content="summary">
<meta name="govuk:analytics:organisations" content="&lt;D12&gt;">
<meta name="govuk:content-id" content="7070ba8c-25c3-49d1-8bcc-42827f1bdcd1">
<meta name="govuk:schema-name" content="html_publication">
<meta name="govuk:publishing-application" content="whitehall">
<meta name="govuk:format" content="html_publication">
<meta name="csrf-token" content="/1nFxcR5pDJHvj/oI2X5t4C9PaLbNe04bQSZah2bTEzcllIXbnYY7yjhIzLg2uLDRPL0AIDxU/0faDzdAqMunw==">
<meta name="csrf-param" content="authenticity_token">
    <meta charset="utf-8">
    <title lang="en">
      Proposal to allow recipients of convalescent plasma for treatment of infection with SARS-CoV-2 to donate plasma for treatment of SARS-CoV-2 infected individuals - GOV.UK
  </title>

    <!--[if gt IE 8]><!--><link rel="stylesheet" media="screen" href="https://www.gov.uk/assets/static/govuk-template-3e3f4a131aca72f9b2e458dfd318f65420aef6ada35539243aac38ebbbbcc64f.css">
<!--<![endif]-->
    <!--[if IE 8]><link rel="stylesheet" media="screen" href="https://www.gov.uk/assets/static/govuk-template-ie8-e4fff1a2ce0e93e66e96db6eedae992a3859b1e608aa46bd3e42ac30f61c58ac.css" /><![endif]-->
    <link rel="stylesheet" media="print" href="https://www.gov.uk/assets/static/govuk-template-print-1076519521c2fffbbf75ab3b0d3b32ee2d96ac7e9778f1cdfac1771eefd1a1c0.css">

    <link rel="stylesheet" media="all" href="https://www.gov.uk/assets/static/fonts-c57ab80a95f2b1764162611b3c98a4c098b356f8e30baf1e50cd63edea464c01.css">
    <!--[if lt IE 9]><script src="https://www.gov.uk/assets/static/ie-a4524544a53d57a7e259b4bb966b9c32557c98c920b77e52d09304642b68401a.js"></script><![endif]-->

    <link rel="shortcut icon" href="https://www.gov.uk/assets/static/favicon-8d811b8c3badbc0b0e2f6e25d3660a96cc0cca7993e6f32e98785f205fc40907.ico" type="image/x-icon">
    <link rel="mask-icon" href="https://www.gov.uk/assets/static/gov.uk_logotype_crown-de738c3fcce8ce2a91b67e89787090dc24a5cda0275ab6b75f6226c5b9619d3d.svg" color="#0b0c0c">
    <link rel="apple-touch-icon" sizes="180x180" href="https://www.gov.uk/assets/static/apple-touch-icon-180x180-ea1cbb1cbbeddfff275dfa6e8e46b84cd530892df79dc4882a8f99b802b49a90.png">
    <link rel="apple-touch-icon" sizes="167x167" href="https://www.gov.uk/assets/static/apple-touch-icon-167x167-181e404a50c572923285fb83f0fbd78da6b4e38e3ce52f8e6b8e29da8586450a.png">
    <link rel="apple-touch-icon" sizes="152x152" href="https://www.gov.uk/assets/static/apple-touch-icon-152x152-02457fcdcee8d309276305af2233d41bfb8fd055e855727d355e61bce7ffa9bb.png">
    <link rel="apple-touch-icon" href="https://www.gov.uk/assets/static/apple-touch-icon-a318f305290c523aed80082456175b46c95350c0eeac93f42e78a71c7a55544e.png">

    <meta name="theme-color" content="#0b0c0c">

    <meta name="viewport" content="width=device-width, initial-scale=1">

      <link rel="stylesheet" media="screen" href="https://www.gov.uk/assets/static/core-layout-de5b3a2096738c4f8a50a76a95d211e052060fa34e6aca769032276c4af07351.css">
<!--[if lte IE 8]><link rel="stylesheet" media="screen" href="https://www.gov.uk/assets/static/core-layout-ie8-773f4cacc5b2d19e924e37800dca2a1e66acd94c661e1cd95a8a165021bdc667.css" /><script>var ieVersion = 8;</script><![endif]-->

<link rel="stylesheet" media="print" href="https://www.gov.uk/assets/static/core-layout-print-3fdeab3ac38fc5d3fd58bd88c6c7e409e22288fc9b9914ee5f852df4743df105.css">



    <meta property="og:image" content="https://www.gov.uk/assets/static/opengraph-image-a1f7d89ffd0782738b1aeb0da37842d8bd0addbd724b8e58c3edbc7287cc11de.png">
  <link rel="stylesheet" media="screen" href="/assets/government-frontend/application-f58103a42980c4e1efd01329de3ea72ee333190ab05a759d629aedc609abdb65.css">
<link rel="stylesheet" media="print" href="/assets/government-frontend/print-0f1ddfe43860cee8af71ac679a95122a9fe14242c09afc1b3cb7ef0cdd8cf3a7.css">
<link rel="canonical" href="https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i">
<meta name="govuk:rendering-application" content="government-frontend">
</head>

  <body>
    <script>document.body.className = ((document.body.className) ? document.body.className + ' js-enabled' : 'js-enabled');</script>

    

    <div id="skiplink-container">
      <div>
        <a href="#content" class="skiplink govuk-link">Skip to main content</a>
      </div>
    </div>

    
<div id="global-cookie-message" class="gem-c-cookie-banner govuk-clearfix" data-module="cookie-banner" role="region" aria-label="cookie banner" data-nosnippet>
  <div class="gem-c-cookie-banner__wrapper govuk-width-container">
    <div class="govuk-grid-row">
      <div class="govuk-grid-column-two-thirds">
        <div class="gem-c-cookie-banner__message">
          <h2 class="govuk-heading-m">Tell us whether you accept cookies</h2>
          <p class="govuk-body">We use <a class="govuk-link" href="/help/cookies">cookies to collect information</a> about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services.</p>
        </div>
          <div class="gem-c-cookie-banner__buttons">
            <div class="gem-c-cookie-banner__button gem-c-cookie-banner__button-accept govuk-grid-column-full govuk-grid-column-one-half-from-desktop">
              


  <button class="gem-c-button govuk-button gem-c-button--inline" type="submit" data-module="track-click" data-accept-cookies="true" data-track-category="cookieBanner" data-track-action="Cookie banner accepted">Accept all cookies</button>


            </div>
            <div class="gem-c-cookie-banner__button gem-c-cookie-banner__button-settings govuk-grid-column-full govuk-grid-column-one-half-from-desktop">
              


  <a class="gem-c-button govuk-button gem-c-button--inline" role="button" data-module="track-click" data-track-category="cookieBanner" data-track-action="Cookie banner settings clicked" href="/help/cookies">Set cookie preferences</a>


            </div>
          </div>
      </div>
    </div>
  </div>

  <div class="gem-c-cookie-banner__confirmation govuk-width-container" tabindex="-1">
    <p class="gem-c-cookie-banner__confirmation-message" role="alert">You’ve accepted all cookies. You can <a class="govuk-link" href="/help/cookies" data-module="track-click" data-track-category="cookieBanner" data-track-action="Cookie banner settings clicked from confirmation">change your cookie settings</a> at any time.</p>
    <button class="gem-c-cookie-banner__hide-button" data-hide-cookie-banner="true" data-module="track-click" data-track-category="cookieBanner" data-track-action="Hide cookie banner">Hide</button>
  </div>
</div>


    <header role="banner" id="global-header" class="">
      <div class="header-wrapper">
        <div class="header-global">
          <div class="header-logo">
            <a href="https://www.gov.uk" title="Go to the GOV.UK homepage" class="content govuk-header__link govuk-header__link--homepage" id="logo" data-module="track-click" data-track-category="homeLinkClicked" data-track-action="homeHeader">
              <span class="govuk-header__logotype">
                <svg aria-hidden="true" focusable="false" class="govuk-header__logotype-crown" xmlns="http://www.w3.org/2000/svg" viewbox="0 0 132 97" height="30" width="36">
                  <path fill="currentColor" fill-rule="evenodd" d="M25 30.2c3.5 1.5 7.7-.2 9.1-3.7 1.5-3.6-.2-7.8-3.9-9.2-3.6-1.4-7.6.3-9.1 3.9-1.4 3.5.3 7.5 3.9 9zM9 39.5c3.6 1.5 7.8-.2 9.2-3.7 1.5-3.6-.2-7.8-3.9-9.1-3.6-1.5-7.6.2-9.1 3.8-1.4 3.5.3 7.5 3.8 9zM4.4 57.2c3.5 1.5 7.7-.2 9.1-3.8 1.5-3.6-.2-7.7-3.9-9.1-3.5-1.5-7.6.3-9.1 3.8-1.4 3.5.3 7.6 3.9 9.1zm38.3-21.4c3.5 1.5 7.7-.2 9.1-3.8 1.5-3.6-.2-7.7-3.9-9.1-3.6-1.5-7.6.3-9.1 3.8-1.3 3.6.4 7.7 3.9 9.1zm64.4-5.6c-3.6 1.5-7.8-.2-9.1-3.7-1.5-3.6.2-7.8 3.8-9.2 3.6-1.4 7.7.3 9.2 3.9 1.3 3.5-.4 7.5-3.9 9zm15.9 9.3c-3.6 1.5-7.7-.2-9.1-3.7-1.5-3.6.2-7.8 3.7-9.1 3.6-1.5 7.7.2 9.2 3.8 1.5 3.5-.3 7.5-3.8 9zm4.7 17.7c-3.6 1.5-7.8-.2-9.2-3.8-1.5-3.6.2-7.7 3.9-9.1 3.6-1.5 7.7.3 9.2 3.8 1.3 3.5-.4 7.6-3.9 9.1zM89.3 35.8c-3.6 1.5-7.8-.2-9.2-3.8-1.4-3.6.2-7.7 3.9-9.1 3.6-1.5 7.7.3 9.2 3.8 1.4 3.6-.3 7.7-3.9 9.1zM69.7 17.7l8.9 4.7V9.3l-8.9 2.8c-.2-.3-.5-.6-.9-.9L72.4 0H59.6l3.5 11.2c-.3.3-.6.5-.9.9l-8.8-2.8v13.1l8.8-4.7c.3.3.6.7.9.9l-5 15.4v.1c-.2.8-.4 1.6-.4 2.4 0 4.1 3.1 7.5 7 8.1h.2c.3 0 .7.1 1 .1.4 0 .7 0 1-.1h.2c4-.6 7.1-4.1 7.1-8.1 0-.8-.1-1.7-.4-2.4V34l-5.1-15.4c.4-.2.7-.6 1-.9zM66 92.8c16.9 0 32.8 1.1 47.1 3.2 4-16.9 8.9-26.7 14-33.5l-9.6-3.4c1 4.9 1.1 7.2 0 10.2-1.5-1.4-3-4.3-4.2-8.7L108.6 76c2.8-2 5-3.2 7.5-3.3-4.4 9.4-10 11.9-13.6 11.2-4.3-.8-6.3-4.6-5.6-7.9 1-4.7 5.7-5.9 8-.5 4.3-8.7-3-11.4-7.6-8.8 7.1-7.2 7.9-13.5 2.1-21.1-8 6.1-8.1 12.3-4.5 20.8-4.7-5.4-12.1-2.5-9.5 6.2 3.4-5.2 7.9-2 7.2 3.1-.6 4.3-6.4 7.8-13.5 7.2-10.3-.9-10.9-8-11.2-13.8 2.5-.5 7.1 1.8 11 7.3L80.2 60c-4.1 4.4-8 5.3-12.3 5.4 1.4-4.4 8-11.6 8-11.6H55.5s6.4 7.2 7.9 11.6c-4.2-.1-8-1-12.3-5.4l1.4 16.4c3.9-5.5 8.5-7.7 10.9-7.3-.3 5.8-.9 12.8-11.1 13.8-7.2.6-12.9-2.9-13.5-7.2-.7-5 3.8-8.3 7.1-3.1 2.7-8.7-4.6-11.6-9.4-6.2 3.7-8.5 3.6-14.7-4.6-20.8-5.8 7.6-5 13.9 2.2 21.1-4.7-2.6-11.9.1-7.7 8.8 2.3-5.5 7.1-4.2 8.1.5.7 3.3-1.3 7.1-5.7 7.9-3.5.7-9-1.8-13.5-11.2 2.5.1 4.7 1.3 7.5 3.3l-4.7-15.4c-1.2 4.4-2.7 7.2-4.3 8.7-1.1-3-.9-5.3 0-10.2l-9.5 3.4c5 6.9 9.9 16.7 14 33.5 14.8-2.1 30.8-3.2 47.7-3.2z">
                  </path>
                  <image src="https://www.gov.uk/assets/static/gov.uk_logotype_crown_invert_trans-203e1db49d3eff430d7dc450ce723c1002542fe1d2bce661b6d8571f14c1043c.png" xlink:href="" class="govuk-header__logotype-crown-fallback-image" width="36" height="32">
                  </image>
                </svg>
                <span class="govuk-header__logotype-text">
                  GOV.UK
                </span>
              </span>
            </a>
          </div>
            <button class="search-toggle js-header-toggle" data-search-toggle-for="search">Show or hide search</button>
  <form id="search" class="site-search govuk-clearfix" action="/search" method="get" role="search" aria-label="Sitewide">
    <div class="content govuk-clearfix">
      <label for="site-search-text">Search</label>
      <input type="search" name="q" id="site-search-text" title="Search" class="js-search-focus">
      <input class="submit" type="submit" value="Search">
    </div>
  </form>

        </div>
        
      </div>
    </header>

      <div id="user-satisfaction-survey-container"></div>


    <div id="global-header-bar"></div>

      
  <!--[if gt IE 7]><!-->
  <div id="global-bar" class="global-bar dont-print" data-module="global-bar" data-global-bar-permanent="true" data-nosnippet>
    <div class="global-bar-message govuk-width-container">


        <div class="global-bar-covid-wrapper">
            <div class="gem-c-action-link gem-c-action-link--light-text gem-c-action-link--with-subtext govuk-!-margin-bottom-0">

      <span class="gem-c-action-link__contents-wrapper">      <span class="gem-c-action-link__link-wrapper">

          <a class="govuk-link gem-c-action-link__link js-call-to-action" href="/coronavirus">
                      Coronavirus (COVID-19)
          

</a>      </span>

        <span class="gem-c-action-link__subtext-wrapper">
            <span class="gem-c-action-link__subtext">Guidance and support</span>
        </span>
</span>
  </div>

        </div>
    </div>

  </div>
  <!--<![endif]-->


  <div id="wrapper" class="direction-ltr">

        
<div class="gem-c-contextual-breadcrumbs">
    


<div class="gem-c-breadcrumbs govuk-breadcrumbs govuk-breadcrumbs--collapse-on-mobile" data-module="track-click">
  <ol class="govuk-breadcrumbs__list">
        <li class="govuk-breadcrumbs__list-item">
          <a data-track-category="homeLinkClicked" data-track-action="homeBreadcrumb" data-track-label="" data-track-options="{}" class="govuk-breadcrumbs__link" href="/">Home</a>
        </li>
        <li class="govuk-breadcrumbs__list-item">
          <a data-track-category="breadcrumbClicked" data-track-action="2" data-track-label="/topic/medicines-medical-devices-blood/blood-regulation-safety" data-track-options='{"dimension28":"3","dimension29":"Blood regulation and safety"}' class="govuk-breadcrumbs__link" href="/topic/medicines-medical-devices-blood/blood-regulation-safety">Blood regulation and safety</a>
        </li>
        <li class="govuk-breadcrumbs__list-item">
          <a data-track-category="breadcrumbClicked" data-track-action="3" data-track-label="/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto" data-track-options='{"dimension28":"3","dimension29":"Use of plasma donations to treat COVID-19: recommendations from SaBTO"}' class="govuk-breadcrumbs__link" href="/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto">Use of plasma donations to treat COVID-19: recommendations from SaBTO</a>
        </li>
  </ol>
</div>


  
</div>


    <main role="main" id="content" class="html-publication" lang="en">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          <div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/department-of-health-and-social-care">
      <span class="gem-c-organisation-logo__name">Department<br>of Health &amp;<br>Social Care</span>
</a>
</div>

        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  <div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text ">
    Proposal to allow recipients of convalescent plasma for treatment of infection with SARS-CoV-2 to donate plasma for treatment of SARS-CoV-2 infected individuals
  </h1>
</div>
  <p class="publication-header__last-changed">Published 5 June 2020</p>

  </header>




<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container" id="contents">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " aria-label="Contents" role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">
        Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#brief-summary" data-track-options='{"dimension29":"\n1. Brief summary"}' href="#brief-summary"><span class="gem-c-contents-list__number">1. </span><span class="gem-c-contents-list__numbered-text">Brief summary</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#proposal" data-track-options='{"dimension29":"\n2. Proposal"}' href="#proposal"><span class="gem-c-contents-list__number">2. </span><span class="gem-c-contents-list__numbered-text">Proposal</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#background" data-track-options='{"dimension29":"\n3. Background"}' href="#background"><span class="gem-c-contents-list__number">3. </span><span class="gem-c-contents-list__numbered-text">Background</span></a>

        </li>
    </ol>
</nav>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-e98134ae65ff5fe99a524d8c383350b3998f91c298dc24b36126e65f1656c578.png">
</p>
<p>
  © Crown copyright 2020
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gsi.gov.uk">psi@nationalarchives.gsi.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<h2 id="brief-summary">
<span class="number">1. </span>Brief summary</h2>

<p>Currently, individuals who have received a transfusion of blood or blood components since January 1980 are not allowed to donate as a risk reduction measure for vCJD.  The UK blood services are about to begin collection of plasma donations from individuals recovering from COVID-19 for clinical trials. Convalescent plasma (<abbr title="convalescent plasma">CP</abbr>) donations will be collected 28 days post recovery from individuals with a previous laboratory confirmed SARS-CoV-2 infection.  If treatment with convalescent plasma is successful it is likely that many individuals treated for SARS-CoV-2 will receive <abbr title="convalescent plasma">CP</abbr>. Once recovered, if these individuals cannot donate this may create a chronic shortage of <abbr title="convalescent plasma">CP</abbr> donors. It is proposed that these individuals be allowed to donate <abbr title="convalescent plasma">CP</abbr> plasma for further treatment of individuals with SARS-CoV-2 infection.</p>

<p>This would be a temporary measure, restricted to donation of plasma from individuals recovering from SARS-CoV-2 infection and will be reviewed in 6 months.</p>

<h2 id="proposal">
<span class="number">2. </span>Proposal</h2>

<p>NHS Blood and Transplant and other UK Blood Services are preparing to collect convalescent plasma (<abbr title="convalescent plasma">CP</abbr>) from individuals recovered from infection with SARS-CoV-2. <abbr title="convalescent plasma">CP</abbr> will be collected 28 days post recovery from individuals with a previous laboratory confirmed SARS-CoV-2 infection.</p>

<p>Trials for <abbr title="convalescent plasma">CP</abbr> are due to start later this month. It is likely that the best donors (for example, those with the highest levels of neutralising antibody) are those who have been sickest and therefore those admitted to hospital and more likely to have been in receipt of <abbr title="convalescent plasma">CP</abbr>. If the trials were to be successful, then there will be a dwindling number of suitable donors of <abbr title="convalescent plasma">CP</abbr> unless the current restriction on blood donors who have previously received blood or a blood component since 1980 being allowed to donate as a risk reduction measure for vCJD is lifted.</p>

<p>Trial participants could receive up to 2 units of plasma from different donors (units would not be pooled). The majority of units will be collected by plasmapheresis, some by whole blood donation although the red cells would not be issued for clinical use.  Also, plasma with a lower titre of neutralizing antibody could be offered to BPL for manufacture of a hyperimmune globulin (this measure is subject to approval of the Commission on Human Medicine) or considered for use as standard fresh frozen plasma.  Donors with high levels of neutralizing antibody may give further donations</p>

<p>The recent risk assessment for vCJD transmission risk by plasma carried out by the Advisory Group for Dangerous Pathogens suggests that the transmission risk from plasma is low with an estimated 6 cases of vCJD over the next 50 years <sup id="fnref:1"><a href="#fn:1" class="govuk-link">1</a></sup>.</p>

<p>The SaBTO paediatric components group looked at the additional risk of stopping importation of around 110,000 units of plasma each year as a risk reduction measure for vCJD for individuals born after 1995. The additional vCJD risk was 1 to 2 cases of vCJD over the next 50 years <sup id="fnref:2"><a href="#fn:2" class="govuk-link">2</a></sup>.</p>

<p>It could be argued that, as trials for treatment of COVID-19 patients with convalescent plasma could reach a similar magnitude to the additional 110,000 units of plasma sourced from UK donors, the vCJD transmission risk to recipients would be similar. As <abbr title="convalescent plasma">CP</abbr> treatment is expected to a short-term measure then the baseline risk would be very small.  This argument comes with many caveats such as the potential opportunity for multiple exposure resulting from recipients of plasma having received <abbr title="convalescent plasma">CP</abbr> from donors who may themselves have received <abbr title="convalescent plasma">CP</abbr> and so on.  Each recipient could receive up to 2 donations.  Also, donors with high levels of neutralizing antibodies could provide several donations.  The true additional risk would need further modelling work although anticipated to remain very small.  If <abbr title="convalescent plasma">CP</abbr> treatment is successful, the benefit to patients would far outweigh this additional risk.</p>

<p>The proposal is that recipients of <abbr title="convalescent plasma">CP</abbr> plasma be allowed to donate plasma for treatment of COVID-19 as the additional vCJD transmission risk from these individuals would remain low and be balanced against the considerable benefit to individuals who require <abbr title="convalescent plasma">CP</abbr> to aid their recovery from COVID-19.</p>

<p>This would be a temporary measure and restricted to <abbr title="convalescent plasma">CP</abbr> donations from individuals who have recovered from SARS-CoV-2 infection.  The measure will be reviewed by SaBTO in 6 months.</p>

<p>After donation(s), it is proposed that individuals will then be deferred from future donation of blood or blood components for routine use. This would be consistent with the existing vCJD risk reduction measure deferring recipients of blood and or blood components since January 1980 for non-<abbr title="convalescent plasma">CP</abbr> donors. However, if <abbr title="convalescent plasma">CP</abbr> is widely used this could result in donor insufficiency so SaBTO may have to consider either a further derogation or removal of the deferral for all donors at some future stage.</p>

<h2 id="background">
<span class="number">3. </span>Background</h2>

<p>Variant Creutzfeldt-Jakob disease (vCJD) is an incurable neurodegenerative disease, part of a group of diseases which can affect humans and other animals known as Transmissible Spongiform Encephalopathies (TSEs) or prion diseases. vCJD arose for the consumption of meat from cattle infected with Bovine Spongiform Encephalopathy (BSE). Stringent measures were put in place to remove BSE from the food supply by the end of 1995.  There have been 178 deaths in the UK from vCJD, the last case was in 2016. However, based on evidence from other prion diseases, vCJD could have a very long incubation period in some individuals, possibly lasting decades.</p>

<p>Following the first documented case of transmission of vCJD from blood in 2004 the Committee on the Microbiological Safety of Blood &amp; Tissues (MSBT) made recommendations to the Department of Health to reduce the risk of transmission of vCJD from blood or blood component donation. This included the exclusion from donation of anyone who had previously received a blood transfusion anywhere in the world after 1 January 1980.  This measure was later extended to previously transfused apheresis donors and donors who were unsure if they had received a blood donation.</p>

<p>The permanent deferral of these individuals was, and still is, an important part of management of vCJD. After, the removal of BSE from the human food chain, the most likely route of serial transmission of vCJD is blood transfusion.</p>

<p>To date, there have been 4 documented cases of transmission of the infectious agent that causes vCJD, 3 resulting in disease. The last case was in 2006. All recipients had received non-leucoreduced red cells; leucoreduction was introduced in 1999 as a risk-reduction measure for vCJD based on data from animal studies that suggested that the white cells contained the highest levels of the infectious agent.</p>

<p>A significant problem with preventing transmission of vCJD from blood donation is the lack of routine diagnostic assays with sufficient sensitivity to detect the very low levels of vCJD prion in blood. Assays which can detect vCJD prion in blood have been recently developed but require specialised laboratories and take too long to complete for routine use.  These assays can detect prion in all components, including plasma from individuals with clinical vCJD <sup id="fnref:3"><a href="#fn:3" class="govuk-link">3</a></sup> <sup id="fnref:4"><a href="#fn:4" class="govuk-link">4</a></sup> and one group has detected prion in plasma from 2 individuals who were asymptomatic at the time of donation <sup id="fnref:3:1"><a href="#fn:3" class="govuk-link">3</a></sup>. Studies on primates have detected vCJD prion in plasma well before the clinical phase <sup id="fnref:5"><a href="#fn:5" class="govuk-link">5</a></sup> <sup id="fnref:6"><a href="#fn:6" class="govuk-link">6</a></sup>. These studies show that plasma donation cannot be excluded as a vCJD transmission risk.  It should be noted however, that all plasma samples reactive for vCJD prion had not been leucoreduced so the impact of this measure is not known.</p>

<p>The Advisory Committee on Dangerous Pathogens (ACDP) have conducted periodic risk assessments on the transmission risk of vCJD from blood.  Early risk assessments had estimated that there was a significant transmission risk from blood but subsequent assessments have consistently revised downwards the risk as the number of cases has been lower than anticipated and with improved understanding of the disease progression and experimental studies.  The last risk assessment, published in 2019, specifically included the transmission risk from plasma donation.  Based on current plasma use in the UK, the assessment indicated there could be 6 cases of vCJD (0-31 95%CI) from plasma transfusion over the next 50 years<sup id="fnref:1:1"><a href="#fn:1" class="govuk-link">1</a></sup>.</p>

<p>It should be noted that the ACDP risk assessment makes assumptions about the population prevalence of vCJD derived from immunohistochemical analysis of appendix samples.  The latest appendix study has recently been published <sup id="fnref:5:1"><a href="#fn:5" class="govuk-link">5</a></sup>. All the appendix studies indicate a UK population of 1:2-4000 per million individuals with the potential to transmit vCJD.  However, this does not appear to reflect clinical cases of vCJD so the risk assessment may be very conservative.</p>

<p>The UK blood services are anticipating collecting around 100,000 units of <abbr title="convalescent plasma">CP</abbr> per year for treatment of SARS CoV-2 infected individuals.  Transfusions on this scale would only be anticipated if <abbr title="convalescent plasma">CP</abbr> is a successful treatment.  The ACDP risk assessment looked at the vCJD transmission risk for plasma based on current use, so an increase of plasma use in the UK would increase the vCJD transmission risk.  The SaBTO paediatric components working group looked at the additional risk of stopping importation of plasma for individuals born on or after 1 January 1996.  Using the ACDP risk assessment, they estimated the additional risk, based on stopping importation of 110,000 units of plasma each year, could result in an additional 1 to 2 cases (0-6 95%CI) of vCJD over the next 50 years<sup id="fnref:2:1"><a href="#fn:2" class="govuk-link">2</a></sup>.</p>

<p>As the SaBTO modelling work was conducted on a similar number of units as anticipated for <abbr title="convalescent plasma">CP</abbr> use, the model could be used to provide a baseline risk for <abbr title="convalescent plasma">CP</abbr> treatment.  However, there would be an additional risk for using <abbr title="convalescent plasma">CP</abbr> donors who had received <abbr title="convalescent plasma">CP</abbr> if they became serial <abbr title="convalescent plasma">CP</abbr> donors (those with high levels of neutralizing antibody).  Additionally, it is possibly that a chain of supply may become established where recipients of <abbr title="convalescent plasma">CP</abbr> donate to recipients of <abbr title="convalescent plasma">CP</abbr> who then, themselves donate and so on multiplying transmission risk.  Without further consideration of these factors it would be important to restrict the use of <abbr title="convalescent plasma">CP</abbr> donation to restricted to <abbr title="convalescent plasma">CP</abbr> use where there would be a significant benefit to recipients compared to the increased vCJD risk.</p>

<div class="footnotes">
  <ol>
    <li id="fn:1">
      <p><a href="https://www.gov.uk/government/publications/vcjd-transmission-by-blood-components-risk-assessment" class="govuk-link">vCJD transmission by blood components: risk assessment</a> [cited 22 April 2020]. <a href="#fnref:1" class="govuk-link">↩</a> <a href="#fnref:1:1" class="govuk-link">↩<sup>2</sup></a></p>
    </li>
    <li id="fn:2">
      <p><a href="https://www.gov.uk/government/publications/risk-reduction-measures-for-variant-creutzfeldt-jakob-disease-pcwg-report" class="govuk-link">Risk reduction measures for variant Creutzfeldt-Jakob disease: PCWG report</a> [cited 22 April 2020]. <a href="#fnref:2" class="govuk-link">↩</a> <a href="#fnref:2:1" class="govuk-link">↩<sup>2</sup></a></p>
    </li>
    <li id="fn:3">
      <p>Bougard D, Brandel J-P, Belondrade M, Beringue V, Segarra C, Fleury H, et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016 Dec 21;8(370):370ra182. <a href="#fnref:3" class="govuk-link">↩</a> <a href="#fnref:3:1" class="govuk-link">↩<sup>2</sup></a></p>
    </li>
    <li id="fn:4">
      <p>Concha-Marambio L, Pritzkow S, Moda F, Tagliavini F, Ironside JW, Schulz PE, et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016 Dec 21;8(370):370ra183. <a href="#fnref:4" class="govuk-link">↩</a></p>
    </li>
    <li id="fn:5">
      <p>Concha-Marambio L, Chacon MA, Soto C. Preclinical Detection of Prions in Blood of Nonhuman Primates Infected with Variant Creutzfeldt-Jakob Disease. Emerg Infect Dis. 2020 Jan;26(1):34–43. <a href="#fnref:5" class="govuk-link">↩</a> <a href="#fnref:5:1" class="govuk-link">↩<sup>2</sup></a></p>
    </li>
    <li id="fn:6">
      <p>Lacroux C, Comoy E, Moudjou M, Perret-Liaudet A, Lugan S, Litaise C, et al. Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog. 2014 Jun;10(6):e1004202. <a href="#fnref:6" class="govuk-link">↩</a></p>
    </li>
  </ol>
</div>
</div>
</div>
</div>

  </div>

  <div data-sticky-element class="govuk-sticky-element">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

  </div>
</div>

    </main>
    
<div class="gem-c-feedback" data-module="feedback">
  
<div class="gem-c-feedback__prompt gem-c-feedback__js-show js-prompt" tabindex="-1">
  <div class="gem-c-feedback__prompt-questions js-prompt-questions">
    <h2 class="gem-c-feedback__prompt-question">Is this page useful?</h2>
    <!-- Maybe button exists only to try and capture clicks by bots -->
    <button data-track-category="yesNoFeedbackForm" data-track-action="ffMaybeClick" aria-expanded="false" style="display: none" hidden="hidden" aria-hidden="true">
      Maybe
    </button>
    
    <ul class="gem-c-feedback__option-list">
      <li class="gem-c-feedback__option-list-item">
        <button class="govuk-button gem-c-feedback__prompt-link js-page-is-useful" data-track-category="yesNoFeedbackForm" data-track-action="ffYesClick">
          Yes <span class="govuk-visually-hidden">this page is useful</span>
        </button>
      </li>
      <li class="gem-c-feedback__option-list-item">
        <button class="govuk-button gem-c-feedback__prompt-link js-toggle-form js-page-is-not-useful" data-track-category="yesNoFeedbackForm" data-track-action="ffNoClick" aria-controls="page-is-not-useful" aria-expanded="false">
          No <span class="govuk-visually-hidden">this page is not useful</span>
        </button>
      </li>
    </ul>
  </div>
  <div class="gem-c-feedback__prompt-questions gem-c-feedback__prompt-success js-prompt-success js-hidden" role="alert">
    Thank you for your feedback
  </div>
  <div class="gem-c-feedback__prompt-questions gem-c-feedback__prompt-questions--something-is-wrong js-prompt-questions">
    <button class="govuk-button gem-c-feedback__prompt-link js-toggle-form js-something-is-wrong" data-track-category="Onsite Feedback" data-track-action="GOV-UK Open Form" aria-controls="something-is-wrong" aria-expanded="false">
      There is something wrong with this page
    </button>
  </div>
</div>

  <form action="/contact/govuk/problem_reports" id="something-is-wrong" class="gem-c-feedback__form js-feedback-form js-hidden" data-track-category="Onsite Feedback" data-track-action="GOV.UK Send Form" method="post">
  <button class="govuk-button govuk-button--secondary gem-c-feedback__close gem-c-feedback__js-show js-close-form" data-track-category="Onsite Feedback" data-track-action="GOV.UK Close Form" aria-controls="something-is-wrong" aria-expanded="true">
    Close
  </button>

  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
      <div class="gem-c-feedback__error-summary gem-c-feedback__js-show js-hidden js-errors" tabindex="-1"></div>

      <input type="hidden" name="url" value="https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i">

      <h3 class="gem-c-feedback__form-heading">Help us improve GOV.UK</h3>
      <p id="feedback_explanation" class="gem-c-feedback__form-paragraph">Don’t include personal or financial information like your National Insurance number or credit card details.</p>

      
<div class="govuk-form-group">
    
  <label for="input-06f48a0b" class="gem-c-label govuk-label">What were you doing?</label>






    <input name="what_doing" class="gem-c-input govuk-input" id="input-06f48a0b" type="text" aria-describedby="feedback_explanation">
</div>

      
<div class="govuk-form-group">
    
  <label for="input-ec9c22b9" class="gem-c-label govuk-label">What went wrong?</label>






    <input name="what_wrong" class="gem-c-input govuk-input" id="input-ec9c22b9" type="text">
</div>

      


  <button class="gem-c-button govuk-button" type="submit">Send</button>


    </div>
  </div>
</form>

  <form action="/contact/govuk/email-survey-signup" id="page-is-not-useful" class="gem-c-feedback__form gem-c-feedback__form--email gem-c-feedback__js-show js-feedback-form js-hidden" data-track-category="yesNoFeedbackForm" data-track-action="Send Form" method="post">
  <button class="govuk-button govuk-button--secondary gem-c-feedback__close js-close-form" data-track-category="yesNoFeedbackForm" data-track-action="ffFormClose" aria-controls="page-is-not-useful" aria-expanded="true">
    Close
  </button>

  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds" id="survey-wrapper">
      <div class="gem-c-feedback__error-summary js-hidden js-errors" tabindex="-1"></div>

      <input name="email_survey_signup[survey_id]" type="hidden" value="footer_satisfaction_survey">
      <input name="email_survey_signup[survey_source]" type="hidden" value="/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i">

      <h3 class="gem-c-feedback__form-heading">Help us improve GOV.UK</h3>
      <p id="survey_explanation" class="gem-c-feedback__form-paragraph">To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.</p>

      
<div class="govuk-form-group">
    
  <label for="input-feeaec0e" class="gem-c-label govuk-label">Email address</label>






    <input name="email_survey_signup[email_address]" class="gem-c-input govuk-input" id="input-feeaec0e" type="email" autocomplete="email" aria-describedby="survey_explanation">
</div>

       


  <button class="gem-c-button govuk-button" type="submit">Send me the survey</button>


    </div>
  </div>
</form>

</div>

  </div>


    <footer class="group js-footer" id="footer" role="contentinfo">
      <div class="govuk-width-container">
        <div class="footer-container govuk-main-wrapper">
              <div class="govuk-grid-row footer-categories" data-module="track-click">
      <div class="govuk-grid-column-two-thirds">
        <h2>Coronavirus (COVID-19)</h2>
        <ul>
          <li>
            <a data-track-category="footerClicked" data-track-action="coronavirusLinks" data-track-label="Coronavirus (COVID-19): guidance and support" href="/coronavirus" class="govuk-link">
               Coronavirus (COVID-19): guidance and support
            </a>
          </li>
        </ul>
      </div>
      <div class="govuk-grid-column-one-third">
        <h2>The UK has left the EU</h2>
        <ul>
          <li>
            <a data-track-category="footerClicked" data-track-action="transitionLinks" data-track-label="Check the new rules for January 2021" href="/transition" class="govuk-link">
               Check the new rules for January 2021
            </a>
          </li>
        </ul>
      </div>
    </div>
    <div class="govuk-grid-row footer-categories" data-module="track-click">
      <div class="govuk-grid-column-two-thirds">
        <h2>Services and information</h2>

        <div class="govuk-grid-row">
          <div class="govuk-grid-column-one-half">
            <ul>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Benefits" href="/browse/benefits">
                  Benefits
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Births, deaths, marriages and care" href="/browse/births-deaths-marriages">
                  Births, deaths, marriages and care
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Business and self-employed" href="/browse/business">
                  Business and self-employed
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="" href="/browse/childcare-parenting">
                  Childcare and parenting
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Citizenship and living in the UK" href="/browse/citizenship">
                  Citizenship and living in the UK
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Crime, justice and the law" href="/browse/justice">
                  Crime, justice and the law
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Disabled people" href="/browse/disabilities">
                  Disabled people
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Driving and transport" href="/browse/driving">
                  Driving and transport
                </a>
              </li>
            </ul>
          </div>
          <div class="govuk-grid-column-one-half">
            <ul>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Education and learning" href="/browse/education">
                  Education and learning
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Employing people" href="/browse/employing-people">
                  Employing people
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Environment and countryside" href="/browse/environment-countryside">
                  Environment and countryside
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Housing and local services" href="/browse/housing-local-services">
                  Housing and local services
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Money and tax" href="/browse/tax">
                  Money and tax
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Passports, travel and living abroad" href="/browse/abroad">
                  Passports, travel and living abroad
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Visas and immigration" href="/browse/visas-immigration">
                  Visas and immigration
                </a>
              </li>
              <li>
                <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Working, jobs and pensions" href="/browse/working">
                  Working, jobs and pensions
                </a>
              </li>
            </ul>
          </div>
        </div>
      </div>

      <div class="govuk-grid-column-one-third">
        <h2>Departments and policy</h2>

        <ul>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="How government works" href="/government/how-government-works">
              How government works
            </a>
          </li>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Departments" href="/government/organisations">
              Departments
            </a>
          </li>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Worldwide" href="/world">
              Worldwide
            </a>
          </li>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Services" href="/search/services">
              Services
            </a>
          </li>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Guidance and regulation" href="/search/guidance-and-regulation">
              Guidance and regulation
            </a>
          </li>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="News and communications" href="/search/news-and-communications">
              News and communications
            </a>
          </li>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Research and statistics" href="/search/research-and-statistics">
              Research and statistics
            </a>
          </li>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Policy papers and consultations" href="/search/policy-papers-and-consultations">
              Policy papers and consultations
            </a>
          </li>
          <li>
            <a class="govuk-link" data-track-category="footerClicked" data-track-action="footerLinks" data-track-label="Transparency and freedom of information releases" href="/search/transparency-and-freedom-of-information-releases">
              Transparency and freedom of information releases
            </a>
          </li>
        </ul>
      </div>
      <hr>
    </div>


          <div class="footer-meta">
            <div class="footer-meta-inner">
                <h2 class="visuallyhidden">Support links</h2>
<ul>
  <li><a class="govuk-link" href="/help">Help</a></li>
  <li><a class="govuk-link" href="/help/privacy-notice">Privacy</a></li>
  <li><a class="govuk-link" href="/help/cookies">Cookies</a></li>
  <li><a class="govuk-link" href="/contact">Contact</a></li>
  <li><a class="govuk-link" href="/help/accessibility-statement">Accessibility statement</a></li>
  <li><a class="govuk-link" href="/help/terms-conditions">Terms and conditions</a></li>
  <li><a class="govuk-link" href="/cymraeg" lang="cy" hreflang="cy">Rhestr o Wasanaethau Cymraeg</a></li>
  <li>
    Built by the
    <a href="https://www.gov.uk/government/organisations/government-digital-service" class="govuk-link">
      Government Digital Service
    </a>
  </li>
</ul>



              <div class="open-government-licence">
                <p class="logo">
                  <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/" rel="license" class="govuk-link open-government-licence__logo-link">
                    Open Government Licence
                  </a>
                </p>
                  <p>All content is available under the <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/" rel="license" class="govuk-link">Open Government Licence v3.0</a>, except where otherwise stated</p>
              </div>
            </div>

            <div class="copyright">
              <a class="govuk-link" href="https://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/uk-government-licensing-framework/crown-copyright/">
                 © Crown copyright
              </a>
            </div>
          </div>
        </div>
      </div>
    </footer>

    <div id="global-app-error" class="app-error hidden"></div>

        <script src="https://www.gov.uk/assets/static/global-bar-init-fdee306aabb4e27c2ab7aabc506b407e6fce180be48271ab093ee168f2d96123.js"></script>
    <script>
      if (GOVUK.globalBarInit) {
        window.GOVUK.globalBarInit.init()
      }
    </script>
  <script src="https://www.gov.uk/assets/static/libs/jquery/jquery-1.12.4-c731c20e2995c576b0509d3bd776f7ab64a66b95363a3b5fae9864299ee594ed.js"></script>
<script src="https://www.gov.uk/assets/static/header-footer-only-d1a69295fbb7da2b29153596e9e82fcb65b0d0982d780cdf7de7e94c3bcc48d9.js"></script>
<script src="https://www.gov.uk/assets/static/surveys-5bda3f4eefbce1d584961c032bcde7c72417fdfb41d514fd849d24f0641e6850.js"></script>



    <script>if (typeof window.GOVUK === 'undefined') document.body.className = document.body.className.replace('js-enabled', '');</script>
  <script src="/assets/government-frontend/application-43321fcd500bad6703a7f981ea72d69c793300fe4a77240235fd2bcc9ce205ff.js"></script><script type="application/ld+json">
  {
  "@context": "http://schema.org",
  "@type": "FAQPage",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i"
  },
  "name": "Proposal to allow recipients of convalescent plasma for treatment of infection with SARS-CoV-2 to donate plasma for treatment of SARS-CoV-2 infected individuals",
  "datePublished": "2020-06-05T15:19:59.000+00:00",
  "dateModified": "2020-06-05T15:25:25.000+00:00",
  "text": null,
  "publisher": {
    "@type": "Organization",
    "name": "GOV.UK",
    "url": "https://www.gov.uk",
    "logo": {
      "@type": "ImageObject",
      "url": "https://www.gov.uk/assets/government-frontend/govuk_publishing_components/govuk-logo-e5962881254c9adb48f94d2f627d3bb67f258a6cbccc969e80abb7bbe4622976.png"
    }
  },
  "image": [
    "https://www.gov.uk/assets/government-frontend/govuk_publishing_components/govuk-schema-placeholder-1x1-5ceffac04f7f6d4f421bd1d36dbb723ef48c15426d7f77f90be80a83af3c747e.png",
    "https://www.gov.uk/assets/government-frontend/govuk_publishing_components/govuk-schema-placeholder-4x3-fcfe16abb1a015848e50d2ea797666a9eaf5158dca38ddfb1e52dc8c0543ab74.png",
    "https://www.gov.uk/assets/government-frontend/govuk_publishing_components/govuk-schema-placeholder-16x9-fcf616879a7b37970df4d2117de962e08f7d057674ef1af6063dcdd529424eee.png"
  ],
  "author": {
    "@type": "Organization",
    "name": "Department of Health and Social Care",
    "url": "https://www.gov.uk/government/organisations/department-of-health-and-social-care"
  },
  "mainEntity": [
    {
      "@type": "Question",
      "name": "\n1. Brief summary",
      "url": "https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i#brief-summary",
      "acceptedAnswer": {
        "@type": "Answer",
        "url": "https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i#brief-summary",
        "text": "<p>Currently, individuals who have received a transfusion of blood or blood components since January 1980 are not allowed to donate as a risk reduction measure for vCJD.  The UK blood services are about to begin collection of plasma donations from individuals recovering from COVID-19 for clinical trials. Convalescent plasma (<abbr title=\"convalescent plasma\">CP</abbr>) donations will be collected 28 days post recovery from individuals with a previous laboratory confirmed SARS-CoV-2 infection.  If treatment with convalescent plasma is successful it is likely that many individuals treated for SARS-CoV-2 will receive <abbr title=\"convalescent plasma\">CP</abbr>. Once recovered, if these individuals cannot donate this may create a chronic shortage of <abbr title=\"convalescent plasma\">CP</abbr> donors. It is proposed that these individuals be allowed to donate <abbr title=\"convalescent plasma\">CP</abbr> plasma for further treatment of individuals with SARS-CoV-2 infection.</p><p>This would be a temporary measure, restricted to donation of plasma from individuals recovering from SARS-CoV-2 infection and will be reviewed in 6 months.</p>"
      }
    },
    {
      "@type": "Question",
      "name": "\n2. Proposal",
      "url": "https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i#proposal",
      "acceptedAnswer": {
        "@type": "Answer",
        "url": "https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i#proposal",
        "text": "<p>NHS Blood and Transplant and other UK Blood Services are preparing to collect convalescent plasma (<abbr title=\"convalescent plasma\">CP</abbr>) from individuals recovered from infection with SARS-CoV-2. <abbr title=\"convalescent plasma\">CP</abbr> will be collected 28 days post recovery from individuals with a previous laboratory confirmed SARS-CoV-2 infection.</p><p>Trials for <abbr title=\"convalescent plasma\">CP</abbr> are due to start later this month. It is likely that the best donors (for example, those with the highest levels of neutralising antibody) are those who have been sickest and therefore those admitted to hospital and more likely to have been in receipt of <abbr title=\"convalescent plasma\">CP</abbr>. If the trials were to be successful, then there will be a dwindling number of suitable donors of <abbr title=\"convalescent plasma\">CP</abbr> unless the current restriction on blood donors who have previously received blood or a blood component since 1980 being allowed to donate as a risk reduction measure for vCJD is lifted.</p><p>Trial participants could receive up to 2 units of plasma from different donors (units would not be pooled). The majority of units will be collected by plasmapheresis, some by whole blood donation although the red cells would not be issued for clinical use.  Also, plasma with a lower titre of neutralizing antibody could be offered to BPL for manufacture of a hyperimmune globulin (this measure is subject to approval of the Commission on Human Medicine) or considered for use as standard fresh frozen plasma.  Donors with high levels of neutralizing antibody may give further donations</p><p>The recent risk assessment for vCJD transmission risk by plasma carried out by the Advisory Group for Dangerous Pathogens suggests that the transmission risk from plasma is low with an estimated 6 cases of vCJD over the next 50 years <sup id=\"fnref:1\"><a href=\"#fn:1\" class=\"govuk-link\">1</a></sup>.</p><p>The SaBTO paediatric components group looked at the additional risk of stopping importation of around 110,000 units of plasma each year as a risk reduction measure for vCJD for individuals born after 1995. The additional vCJD risk was 1 to 2 cases of vCJD over the next 50 years <sup id=\"fnref:2\"><a href=\"#fn:2\" class=\"govuk-link\">2</a></sup>.</p><p>It could be argued that, as trials for treatment of COVID-19 patients with convalescent plasma could reach a similar magnitude to the additional 110,000 units of plasma sourced from UK donors, the vCJD transmission risk to recipients would be similar. As <abbr title=\"convalescent plasma\">CP</abbr> treatment is expected to a short-term measure then the baseline risk would be very small.  This argument comes with many caveats such as the potential opportunity for multiple exposure resulting from recipients of plasma having received <abbr title=\"convalescent plasma\">CP</abbr> from donors who may themselves have received <abbr title=\"convalescent plasma\">CP</abbr> and so on.  Each recipient could receive up to 2 donations.  Also, donors with high levels of neutralizing antibodies could provide several donations.  The true additional risk would need further modelling work although anticipated to remain very small.  If <abbr title=\"convalescent plasma\">CP</abbr> treatment is successful, the benefit to patients would far outweigh this additional risk.</p><p>The proposal is that recipients of <abbr title=\"convalescent plasma\">CP</abbr> plasma be allowed to donate plasma for treatment of COVID-19 as the additional vCJD transmission risk from these individuals would remain low and be balanced against the considerable benefit to individuals who require <abbr title=\"convalescent plasma\">CP</abbr> to aid their recovery from COVID-19.</p><p>This would be a temporary measure and restricted to <abbr title=\"convalescent plasma\">CP</abbr> donations from individuals who have recovered from SARS-CoV-2 infection.  The measure will be reviewed by SaBTO in 6 months.</p><p>After donation(s), it is proposed that individuals will then be deferred from future donation of blood or blood components for routine use. This would be consistent with the existing vCJD risk reduction measure deferring recipients of blood and or blood components since January 1980 for non-<abbr title=\"convalescent plasma\">CP</abbr> donors. However, if <abbr title=\"convalescent plasma\">CP</abbr> is widely used this could result in donor insufficiency so SaBTO may have to consider either a further derogation or removal of the deferral for all donors at some future stage.</p>"
      }
    },
    {
      "@type": "Question",
      "name": "\n3. Background",
      "url": "https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i#background",
      "acceptedAnswer": {
        "@type": "Answer",
        "url": "https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto/proposal-to-allow-recipients-of-convalescent-plasma-for-treatment-of-infection-with-sars-cov-2-to-donate-plasma-for-treatment-of-sars-cov-2-infected-i#background",
        "text": "<p>Variant Creutzfeldt-Jakob disease (vCJD) is an incurable neurodegenerative disease, part of a group of diseases which can affect humans and other animals known as Transmissible Spongiform Encephalopathies (TSEs) or prion diseases. vCJD arose for the consumption of meat from cattle infected with Bovine Spongiform Encephalopathy (BSE). Stringent measures were put in place to remove BSE from the food supply by the end of 1995.  There have been 178 deaths in the UK from vCJD, the last case was in 2016. However, based on evidence from other prion diseases, vCJD could have a very long incubation period in some individuals, possibly lasting decades.</p><p>Following the first documented case of transmission of vCJD from blood in 2004 the Committee on the Microbiological Safety of Blood &amp; Tissues (MSBT) made recommendations to the Department of Health to reduce the risk of transmission of vCJD from blood or blood component donation. This included the exclusion from donation of anyone who had previously received a blood transfusion anywhere in the world after 1 January 1980.  This measure was later extended to previously transfused apheresis donors and donors who were unsure if they had received a blood donation.</p><p>The permanent deferral of these individuals was, and still is, an important part of management of vCJD. After, the removal of BSE from the human food chain, the most likely route of serial transmission of vCJD is blood transfusion.</p><p>To date, there have been 4 documented cases of transmission of the infectious agent that causes vCJD, 3 resulting in disease. The last case was in 2006. All recipients had received non-leucoreduced red cells; leucoreduction was introduced in 1999 as a risk-reduction measure for vCJD based on data from animal studies that suggested that the white cells contained the highest levels of the infectious agent.</p><p>A significant problem with preventing transmission of vCJD from blood donation is the lack of routine diagnostic assays with sufficient sensitivity to detect the very low levels of vCJD prion in blood. Assays which can detect vCJD prion in blood have been recently developed but require specialised laboratories and take too long to complete for routine use.  These assays can detect prion in all components, including plasma from individuals with clinical vCJD <sup id=\"fnref:3\"><a href=\"#fn:3\" class=\"govuk-link\">3</a></sup> <sup id=\"fnref:4\"><a href=\"#fn:4\" class=\"govuk-link\">4</a></sup> and one group has detected prion in plasma from 2 individuals who were asymptomatic at the time of donation <sup id=\"fnref:3:1\"><a href=\"#fn:3\" class=\"govuk-link\">3</a></sup>. Studies on primates have detected vCJD prion in plasma well before the clinical phase <sup id=\"fnref:5\"><a href=\"#fn:5\" class=\"govuk-link\">5</a></sup> <sup id=\"fnref:6\"><a href=\"#fn:6\" class=\"govuk-link\">6</a></sup>. These studies show that plasma donation cannot be excluded as a vCJD transmission risk.  It should be noted however, that all plasma samples reactive for vCJD prion had not been leucoreduced so the impact of this measure is not known.</p><p>The Advisory Committee on Dangerous Pathogens (ACDP) have conducted periodic risk assessments on the transmission risk of vCJD from blood.  Early risk assessments had estimated that there was a significant transmission risk from blood but subsequent assessments have consistently revised downwards the risk as the number of cases has been lower than anticipated and with improved understanding of the disease progression and experimental studies.  The last risk assessment, published in 2019, specifically included the transmission risk from plasma donation.  Based on current plasma use in the UK, the assessment indicated there could be 6 cases of vCJD (0-31 95%CI) from plasma transfusion over the next 50 years<sup id=\"fnref:1:1\"><a href=\"#fn:1\" class=\"govuk-link\">1</a></sup>.</p><p>It should be noted that the ACDP risk assessment makes assumptions about the population prevalence of vCJD derived from immunohistochemical analysis of appendix samples.  The latest appendix study has recently been published <sup id=\"fnref:5:1\"><a href=\"#fn:5\" class=\"govuk-link\">5</a></sup>. All the appendix studies indicate a UK population of 1:2-4000 per million individuals with the potential to transmit vCJD.  However, this does not appear to reflect clinical cases of vCJD so the risk assessment may be very conservative.</p><p>The UK blood services are anticipating collecting around 100,000 units of <abbr title=\"convalescent plasma\">CP</abbr> per year for treatment of SARS CoV-2 infected individuals.  Transfusions on this scale would only be anticipated if <abbr title=\"convalescent plasma\">CP</abbr> is a successful treatment.  The ACDP risk assessment looked at the vCJD transmission risk for plasma based on current use, so an increase of plasma use in the UK would increase the vCJD transmission risk.  The SaBTO paediatric components working group looked at the additional risk of stopping importation of plasma for individuals born on or after 1 January 1996.  Using the ACDP risk assessment, they estimated the additional risk, based on stopping importation of 110,000 units of plasma each year, could result in an additional 1 to 2 cases (0-6 95%CI) of vCJD over the next 50 years<sup id=\"fnref:2:1\"><a href=\"#fn:2\" class=\"govuk-link\">2</a></sup>.</p><p>As the SaBTO modelling work was conducted on a similar number of units as anticipated for <abbr title=\"convalescent plasma\">CP</abbr> use, the model could be used to provide a baseline risk for <abbr title=\"convalescent plasma\">CP</abbr> treatment.  However, there would be an additional risk for using <abbr title=\"convalescent plasma\">CP</abbr> donors who had received <abbr title=\"convalescent plasma\">CP</abbr> if they became serial <abbr title=\"convalescent plasma\">CP</abbr> donors (those with high levels of neutralizing antibody).  Additionally, it is possibly that a chain of supply may become established where recipients of <abbr title=\"convalescent plasma\">CP</abbr> donate to recipients of <abbr title=\"convalescent plasma\">CP</abbr> who then, themselves donate and so on multiplying transmission risk.  Without further consideration of these factors it would be important to restrict the use of <abbr title=\"convalescent plasma\">CP</abbr> donation to restricted to <abbr title=\"convalescent plasma\">CP</abbr> use where there would be a significant benefit to recipients compared to the increased vCJD risk.</p><div class=\"footnotes\">\n  <ol>\n    <li id=\"fn:1\">\n      <p><a href=\"https://www.gov.uk/government/publications/vcjd-transmission-by-blood-components-risk-assessment\" class=\"govuk-link\">vCJD transmission by blood components: risk assessment</a> [cited 22 April 2020]. <a href=\"#fnref:1\" class=\"govuk-link\">↩</a> <a href=\"#fnref:1:1\" class=\"govuk-link\">↩<sup>2</sup></a></p>\n    </li>\n    <li id=\"fn:2\">\n      <p><a href=\"https://www.gov.uk/government/publications/risk-reduction-measures-for-variant-creutzfeldt-jakob-disease-pcwg-report\" class=\"govuk-link\">Risk reduction measures for variant Creutzfeldt-Jakob disease: PCWG report</a> [cited 22 April 2020]. <a href=\"#fnref:2\" class=\"govuk-link\">↩</a> <a href=\"#fnref:2:1\" class=\"govuk-link\">↩<sup>2</sup></a></p>\n    </li>\n    <li id=\"fn:3\">\n      <p>Bougard D, Brandel J-P, Belondrade M, Beringue V, Segarra C, Fleury H, et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016 Dec 21;8(370):370ra182. <a href=\"#fnref:3\" class=\"govuk-link\">↩</a> <a href=\"#fnref:3:1\" class=\"govuk-link\">↩<sup>2</sup></a></p>\n    </li>\n    <li id=\"fn:4\">\n      <p>Concha-Marambio L, Pritzkow S, Moda F, Tagliavini F, Ironside JW, Schulz PE, et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016 Dec 21;8(370):370ra183. <a href=\"#fnref:4\" class=\"govuk-link\">↩</a></p>\n    </li>\n    <li id=\"fn:5\">\n      <p>Concha-Marambio L, Chacon MA, Soto C. Preclinical Detection of Prions in Blood of Nonhuman Primates Infected with Variant Creutzfeldt-Jakob Disease. Emerg Infect Dis. 2020 Jan;26(1):34–43. <a href=\"#fnref:5\" class=\"govuk-link\">↩</a> <a href=\"#fnref:5:1\" class=\"govuk-link\">↩<sup>2</sup></a></p>\n    </li>\n    <li id=\"fn:6\">\n      <p>Lacroux C, Comoy E, Moudjou M, Perret-Liaudet A, Lugan S, Litaise C, et al. Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog. 2014 Jun;10(6):e1004202. <a href=\"#fnref:6\" class=\"govuk-link\">↩</a></p>\n    </li>\n  </ol>\n</div>"
      }
    }
  ]
}
</script><script type="application/ld+json">
  {
  "@context": "http://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [
    {
      "@type": "ListItem",
      "position": 1,
      "item": {
        "name": "Home",
        "@id": "https://www.gov.uk/"
      }
    },
    {
      "@type": "ListItem",
      "position": 2,
      "item": {
        "name": "Blood regulation and safety",
        "@id": "https://www.gov.uk/topic/medicines-medical-devices-blood/blood-regulation-safety"
      }
    },
    {
      "@type": "ListItem",
      "position": 3,
      "item": {
        "name": "Use of plasma donations to treat COVID-19: recommendations from SaBTO",
        "@id": "https://www.gov.uk/government/publications/use-of-blood-plasma-donations-to-treat-covid-19-recommendations-from-sabto"
      }
    }
  ]
}
</script>
</body>
</html>
